Name: MDMB–CHMICA, MMB–CHMINACA (Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate)
Type: Synthetic cannabinoid
AKA: MDMB-CHMICA, MMB-CHMINACA
|
II. Natural Derivative
Synthetic substance, no natural derivative
|
|
IV. History
MDMB-CHMICA and MMB-CHMINACA, synthetic cannabinoids developed in the 2010s, are part of research into cannabinoid receptors. They are known for their psychoactive effects and have been associated with recreational use and regulatory controls.
|
V. Legal Information
MDMB-CHMINACA and MMB-CHMINACA, synthetic cannabinoids, are often regulated under analog laws due to their psychoactive effects. Their status varies by jurisdiction.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
VI. Physical Effects
MDMB-CHMICA and MMB-CHMINACA are synthetic cannabinoids with intense psychoactive effects. As an upper, they induce euphoria and altered perception. Short-term effects include increased heart rate and potential anxiety, while long-term use may lead to psychological issues. Overdose risks involve severe agitation and cardiovascular problems. Safe use involves cautious dosing, and recent research highlights their potency and risks. |
VII. Psychological Effects
MDMB-CHMINACA, a synthetic cannabinoid, affects cannabinoid receptors, causing altered mood and perception. Immediate effects include euphoria and relaxation, while long-term use may lead to cognitive impairments and psychological issues. Effects last several hours, with risks of severe mental health disturbances and dependence with prolonged use.
|
VIII. Culture
MDMB-CHMINACA is a synthetic cannabinoid, classifying it as a downer. Short-term use induces relaxation and altered perceptions, while long-term use can lead to dependence and cognitive impairment. Overdose risks include severe sedation, cognitive effects, and potential psychosis. Safe dosages are not well-established, with minimal use recommended. Recent research highlights its high potency and associated cognitive risks. Physical effects include drowsiness, altered perceptions, and potential for impaired motor skills.
|